European Journal of Clinical Pharmacology

, Volume 27, Issue 1, pp 61–65 | Cite as

A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome

  • M. H. A. Rustin
  • S. M. Grimes
  • I. B. Kovacs
  • E. D. Cooke
  • S. A. Bowcock
  • S. O. Sowemimo-Coker
  • P. Turner
  • J. D. T. Kirby


Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.

Key words

thromboxane synthetase inhibitors Raynaud's syndrome systemic sclerosis UK-38,485 ischaemic attacks red blood cell rheology 


  1. 1.
    Dowd PM, Martin MFR, Cooke ED, Bowcock SA, Dieppe PA, Kirby JDT (1982) Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 106: 81–89Google Scholar
  2. 2.
    Belch JJF, Drury JK, Capell H, Forbes CD, Newman P, McKenzie F, Lieberman P, Prentice CRM (1983) Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1: 313–315Google Scholar
  3. 3.
    Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Int Med 96: 610–613Google Scholar
  4. 4.
    Parry MJ, Randall MJ, Hawkeswood E, Cross PE, Dickinson RP (1982) Enhanced production of prostacyclin in blood after treatment with selective thromboxane synthetase inhibitor, UK-38,485. Br J Pharmacol 77: 547PGoogle Scholar
  5. 5.
    Fischer S, Struppler M, Bohlig B, Bernutz C, Wober W, Weber PC (1983) The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. Circulation 68: 821–826Google Scholar
  6. 6.
    Orchard MA, Blair IA, Dollery CT, Lewis PJ (1983) Blood can synthesise prostacyclin. Lancet 2: 565Google Scholar
  7. 7.
    Belch JJF, Cormie J, Newman P, McLaren M, Barbenell J, Capell H, Lieberman P, Forbes CD, Prentice CRM (1983) Dazoxiben, a thromboxane synthetase inhibitor in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol 15: 113s-116sGoogle Scholar
  8. 8.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 23: 581–590Google Scholar
  9. 9.
    Cooke ED, Bowcock SA, Smith AT (1984) A mathematical model for the vascular behaviour of the hands in response to cold stress. Vascular diagnosis and therapy (in press)Google Scholar
  10. 10.
    Challoner AVJ, Ramsay CA (1974) A photoelectric plethysmograph for the measurement of cutaneous blood flow. Phys Med Biol 19: 317–328Google Scholar
  11. 11.
    Kovacs IB, Sowemimo-Coker SO, Kirby JDT, Turner P (1983) Altered behaviour of erythrocytes in scleroderma. Clin Sci 65: 515–519Google Scholar
  12. 12.
    Streichman S, Segal E, Tatarsky I, Marmur A (1981) Moving boundary electrophoresis and sialic acid content of normal and polycythaemic red blood cells. Br J Haematol 48: 273–279Google Scholar
  13. 13.
    Bertele V, Cerletti C, Schieppatia A, Di Minno G, De Gaetano G (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1: 1057–1058Google Scholar
  14. 14.
    Bertele V, Tomasiak M, Falanga A, Cerletti C, De Gaetano G (1982) Aspirin inhibits platelet aggregation but not because it prevents thromboxane synthesis. Lancet 2: 775Google Scholar
  15. 15.
    Nijkamp FP, Moncada S, White HL, Vane JR (1977) Diversion of prostaglandin endoperoxide metabolism by selective inhibition of Thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol 44: 179–186Google Scholar
  16. 16.
    Needleman P, Wyche A, Raz A (1979) Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 63: 345–349Google Scholar
  17. 17.
    Fitzgerald GA, Brash AR, Oates JA (1983) Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 71: 1336–1343Google Scholar
  18. 18.
    Tyler HM, Saxton CAPD, Parry MJ (1981) Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet 1: 629–632Google Scholar
  19. 19.
    Miller OV, Gorman RR (1979) Evidence for distinct prostaglandin I2 and D2 receptors in human platelets. J Pharmacol Exp Ther 210: 134–140Google Scholar
  20. 20.
    Vermylen J, Deckmyn H (1983) Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. Br J Clin Pharmacol 15: 17s-22s.Google Scholar
  21. 21.
    Dowd PM, Kovacs IB, Bland CJH, Kirby JDT (1981) Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J 283: 350Google Scholar
  22. 22.
    Kovacs IB, O'Grady J (1984) Prostacyclin increases filterability of normal and rigidified human red blood cells in vitro. Agents Actions 14: 306–310Google Scholar
  23. 23.
    Horrobin DF, Jenkins K, Manku MS (1983) Raynaud's phenomenon, histamine, and prostaglandins. Lancet 1: 747–748Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • M. H. A. Rustin
    • 1
  • S. M. Grimes
    • 1
  • I. B. Kovacs
    • 1
  • E. D. Cooke
    • 2
  • S. A. Bowcock
    • 2
  • S. O. Sowemimo-Coker
    • 3
  • P. Turner
    • 3
  • J. D. T. Kirby
    • 1
  1. 1.Department of DermatologySt. Bartholomew's HospitalLondonEngland
  2. 2.Department of Medical ElectronicsSt. Bartholomew's HospitalLondonEngland
  3. 3.Department of Clinical PharmacologySt. Bartholomew's HospitalLondonEngland

Personalised recommendations